Abstract:RNA splicing, a crucial transesterification-based process by which noncoding regions are removed from premature RNA to create mature mRNA, regulates various cellular functions, such as proliferation, survival, and differentiation. Clinical and functional studies over the past 10 y have confirmed that mutations in RNA splicing factors are among the most recurrent genetic abnormalities in hematologic neoplasms, including myeloid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, and clonal hematopoiesis. These findings indicate an important role for splicing factor mutations in the development of clonal hematopoietic disorders. Mutations in core or accessory components of the RNA spliceosome complex alter splicing sites in a manner of change of function. These changes can result in the dysregulation of cancer-associated gene expression and the generation of novel mRNA transcripts, some of which are not only critical to disease development but may be also serving as potential therapeutic targets. Furthermore, multiple studies have revealed that hematopoietic cells bearing mutations in splicing factors depend on the expression of the residual wild-type allele for survival, and these cells are more sensitive to reduced expression of wild-type splicing factors or chemical perturbations of the splicing machinery. These findings suggest a promising possibility for developing novel therapeutic opportunities in tumor cells based on mutations in splicing factors. Here, we combine current knowledge of the mechanistic and functional effects of frequently mutated splicing factors in normal hematopoiesis and the effects of their mutations in hematologic malignancies. Moreover, we discuss the development of potential therapeutic opportunities based on these mutations.

Splicing Dysregulation in Cancer: from Mechanistic Understanding to a New Class of Therapeutic Targets

Dysregulation and therapeutic targeting of RNA splicing in cancer

RNA splicing dysregulation and the hallmarks of cancer

RNA Splicing Alterations in Lung Cancer Pathogenesis and Therapy

Steering research on mRNA splicing in cancer towards clinical translation

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

Therapeutic strategies for aberrant splicing in cancer and genetic disorders

Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Targeting splicing factors for cancer therapy

Alternative splicing and cancer: a systematic review

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

Targeting Dysregulated Splicing Factors in Cancer: Lessons Learned from RBM10 Deficiency.

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

A Widespread Length-Dependent Splicing Dysregulation in Cancer

Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer

Roles and mechanisms of alternative splicing in cancer — implications for care

The role of alternative splicing in human cancer progression.

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform

Significance of Alternative Splicing in Cancer Cells.